Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 11, pp 1498–1505 | Cite as

Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan

  • Yoshihiro NishidaEmail author
  • Akira Kawai
  • Junya Toguchida
  • Akira Ogose
  • Keisuke Ae
  • Toshiyuki Kunisada
  • Yoshihiro Matsumoto
  • Tomoya Matsunobu
  • Kunihiko Takahashi
  • Kazuki Nishida
  • Toshifumi Ozaki
Original Article
  • 60 Downloads

Abstract

Background

Treatment modality of desmoid-type fibromatosis (DF) has changed from surgery with a wide surgical margin to conservative treatment. In this study, tumor characteristics of DF, transition of the treatment modality, and clinical outcome of surgical treatment were analyzed based on data obtained from the bone and soft tissue tumor registry established in Japan.

Methods

Data were collected as registration data and follow-up data. Five hundred and thirty registered cases of DF were identified, including 223 cases with follow-up data with or without surgical treatment.

Results

The number of registered patients increased gradually. The frequency of surgical treatment was gradually reduced year by year. The 3-year local recurrence free survival (LRFS) was 77.7%, with tumor location and size tending to correlate with LRFS. Interestingly, there was no significant difference in LRFS between wide and marginal margin (P = 0.34).

Conclusions

The treatment modality has shifted from surgical to conservative treatment, with risk factors for surgical treatment similar to those noted in previous studies. The National registry system is crucial for a rare disease such as DF, and in the future, a population based registry system should be established to better comprehend the actual status of DF.

Keywords

Desmoid-type fibromatosis Registry Treatment modality Marginal resection 

Notes

Acknowledgements

This work was supported in part by the Ministry of Health, Labor and Welfare of Japan, and the Ministry of Education, Culture, Sports, Science and Technology of Japan [Grant-in-Aid 17H01585 for Scientific Research (A)], and the National Cancer Center Research and Development Fund (29-A-3). We thank the hospitals and medical staff involved in the bone and soft tissue tumor registry. We also thank Ms Nakano and Ishihama for their support of the registry.

Compliance with ethical standards

Conflict of interest

Yoshihiro Nishida has no conflict of interest regarding this study, Akira Kawai has no conflict of interest regarding this study, Junya Toguchida has no conflict of interest regarding this study, Akira Ogose has no conflict of interest regarding this study, Keisuke Ae has no conflict of interest regarding this study, Toshiyuki Kunisada has no conflict of interest regarding this study, Yoshihiro Matsumoto has no conflict of interest regarding this study, Tomoya Matsunobu has no conflict of interest regarding this study, Kunihiko Takahashi has no conflict of interest regarding this study, Kazuki Nishida has no conflict of interest regarding this study, Toshifumi Ozaki has no conflict of interest regarding this study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was waived because of the study based on the national registry data.

References

  1. 1.
    Kasper B, Ströbel P, Hohenberger P (2011) Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 16:682–693CrossRefGoogle Scholar
  2. 2.
    Reitamo JJ, Hayry P, Nykyri E et al (1982) The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 77:665–673CrossRefGoogle Scholar
  3. 3.
    Gronchi A, Casali PG, Mariani L et al (2003) Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 21:1390–1397CrossRefGoogle Scholar
  4. 4.
    Lev D, Kotilingam D, Wei C et al (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25:1785–1791CrossRefGoogle Scholar
  5. 5.
    Merchant NB, Lewis JJ, Woodruff JM et al (1999) Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 86:2045–2052CrossRefGoogle Scholar
  6. 6.
    Honeyman JN, Theilen TM, Knowles MA et al (2013) Desmoid fibromatosis in children and adolescents: a conservative approach to management. J Pediatr Surg 48:62–66CrossRefGoogle Scholar
  7. 7.
    Bonvalot S, Eldweny H, Haddad V et al (2008) Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 34:462–468CrossRefGoogle Scholar
  8. 8.
    Fiore M, Rimareix F, Mariani L et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16:2587–2593CrossRefGoogle Scholar
  9. 9.
    ESMO/European Sarcoma Network Working Group (2012) Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):92–99Google Scholar
  10. 10.
    Dangoor A, Seddon B, Gerrand C et al (2016) UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 6:20CrossRefGoogle Scholar
  11. 11.
    Grimer R, Judson I, Peake D, Seddon B (2010) Guidelines for the management of soft tissue sarcomas. Sarcoma 2010:506182PubMedPubMedCentralGoogle Scholar
  12. 12.
    Fukushima T, Ogura K, Akiyama T et al (2018) Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. BMC Musculoskelet Disord 19:297CrossRefGoogle Scholar
  13. 13.
    Ogura K, Higashi T, Kawai A (2017) Statistics of bone sarcoma in Japan: report from the bone and soft tissue tumor registry in Japan. J Orthop Sci 22:133–143CrossRefGoogle Scholar
  14. 14.
    Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553–3558CrossRefGoogle Scholar
  15. 15.
    Kawaguchi N, Ahmed AR, Matsumoto S et al (2004) The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res 419:165–172CrossRefGoogle Scholar
  16. 16.
    Gronchi A, Colombo C, Le Pechoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25:578–583CrossRefGoogle Scholar
  17. 17.
    Nishida Y, Tsukushi S, Shido Y et al (2012) Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality. Cancers (Basel) 4:88–99CrossRefGoogle Scholar
  18. 18.
    Penel N, Le Cesne A, Bonvalot S et al (2017) Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer 83:125–131CrossRefGoogle Scholar
  19. 19.
    Bonvalot S, Desai A, Coppola S et al (2012) The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 23(Suppl 10):x158–x166CrossRefGoogle Scholar
  20. 20.
    Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Jt Surg Am 96:631–638CrossRefGoogle Scholar
  21. 21.
    Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17:158–167CrossRefGoogle Scholar
  22. 22.
    Shido Y, Nishida Y, Nakashima H et al (2009) Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 129:929–933CrossRefGoogle Scholar
  23. 23.
    Klein WA, Miller HH, Anderson M, DeCosse JJ (1987) The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863–2868CrossRefGoogle Scholar
  24. 24.
    Nishida Y, Tsukushi S, Shido Y et al (2010) Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 28:107–109CrossRefGoogle Scholar
  25. 25.
    Hansmann A, Adolph C, Vogel T et al (2004) High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100:612–620CrossRefGoogle Scholar
  26. 26.
    Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer 60:1108–1112CrossRefGoogle Scholar
  27. 27.
    Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92:1259–1264CrossRefGoogle Scholar
  28. 28.
    Nishida Y, Tsukushi S, Urakawa H et al (2015) Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status. Int J Clin Oncol 20:1211–1217CrossRefGoogle Scholar
  29. 29.
    Skapek SX, Hawk BJ, Hoffer FA et al (1998) Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 16:3021–3027CrossRefGoogle Scholar
  30. 30.
    Crago AM, Denton B, Salas S et al (2013) A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg 258:347–353CrossRefGoogle Scholar
  31. 31.
    Peng PD, Hyder O, Mavros MN et al (2012) Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol 19:4036–4042CrossRefGoogle Scholar
  32. 32.
    Mullen JT, Delaney TF, Kobayashi WK et al (2012) Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 19:4028–4035CrossRefGoogle Scholar
  33. 33.
    Colombo C, Miceli R, Lazar AJ et al (2013) CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 119:3696–3702CrossRefGoogle Scholar
  34. 34.
    Domont J, Salas S, Lacroix L et al (2010) High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 102:1032–1036CrossRefGoogle Scholar
  35. 35.
    Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518–1527CrossRefGoogle Scholar
  36. 36.
    Leithner A, Gapp M, Leithner K et al (2004) Margins in extra-abdominal desmoid tumors: a comparative analysis. J Surg Oncol 86:152–156CrossRefGoogle Scholar
  37. 37.
    Le Guellec S, Soubeyran I, Rochaix P et al (2012) CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol 25:1551–1558CrossRefGoogle Scholar
  38. 38.
    Nishida Y, Tsukushi S, Urakawa H et al (2016) Simple resection of truncal desmoid tumors: a case series. Oncol Lett 12:1564–1568CrossRefGoogle Scholar
  39. 39.
    Hamada S, Futamura N, Ikuta K et al (2014) CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS One 9:e96391CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Yoshihiro Nishida
    • 1
    • 2
    Email author
  • Akira Kawai
    • 3
  • Junya Toguchida
    • 4
  • Akira Ogose
    • 5
  • Keisuke Ae
    • 6
  • Toshiyuki Kunisada
    • 7
  • Yoshihiro Matsumoto
    • 8
  • Tomoya Matsunobu
    • 9
  • Kunihiko Takahashi
    • 10
  • Kazuki Nishida
    • 10
  • Toshifumi Ozaki
    • 11
  1. 1.Department of Orthopedic SurgeryNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Rehabilitation MedicineNagoya University HospitalNagoyaJapan
  3. 3.Department of Musculoskeletal OncologyNational Cancer Center HospitalTokyoJapan
  4. 4.Department of Orthopaedic Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan
  5. 5.Department of Orthopedic Surgery, Uonuma Institute of Community MedicineNiigata University Medical and Dental HospitalMinamiuonumaJapan
  6. 6.Department of Orthopedic SurgeryCancer Institute HospitalTokyoJapan
  7. 7.Department of Medical Materials for Musculoskeletal ReconstructionOkayama University Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayamaJapan
  8. 8.Department of Orthopedic SurgeryKyushu UniversityFukuokaJapan
  9. 9.Department of Orthopedic SurgeryKyushu Rosai HospitalSonekitachoKitakyushu, FukuokaJapan
  10. 10.Department of BiostatisticsNagoya University Graduate School of MedicineNagoyaJapan
  11. 11.Department of Orthopedic SurgeryOkayama University Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayamaJapan

Personalised recommendations